Plan in Medical Technology

Encorium Announces the Initiation of a Strategic Partnership With Prologue Research After the Postponement of Negotiations Regarding Its Planned Acquisition; Strategic Reorganization and Cost Reduction Plan Initiated as Strategic Alternatives are Investig

WAYNE, Penn., Sept. 22 /PRNewswire-FirstCall/ -- Encorium Group, Inc. (Nasdaq: ENCO ), a full service multinational clinical research organization (CRO) conducting studies in over 30 countries for many of the world's leading pharmaceutical and biotechnology companies, today announced that at ...

Cylex Announces Plan for Multi-Center Trial of ImmuKnow(R) Assay in South Korea

Seven Korean medical centers to collaborate on studies of immunosuppression in kidney transplant patients and role of cell-mediated immunity COLUMBIA, Md., Aug. 28 /PRNewswire/ -- "Cylex, Inc., in association with our Korean distributor, Sun Woo Biotech, is delighted to be able to announce ou...

Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters

Company Focused on IND-Enabling Work with Protein Therapeutics that Modulate Alternative Pathway of Complement System CAMBRIDGE, Mass., July 23 /PRNewswire/ -- Taligen Therapeutics Inc. today announced it has initiated a corporate growth plan with the appointment of Abbie Celniker,...

Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)

Phase 2 Study for NKTR-102 Will Target Newly-Identified K-Ras Mutated Oncogene Population in Patients with Advanced Colorectal Cancer New Phase 2 Clinical Trials Will Evaluate NKTR-102 in Advanced Breast and Ovarian Cancers SAN CARLOS, Calif., June 2 /PRNewswire...

TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds

- Plan Also Calls for Expansion of Business Development, Streamlining of Operations - - Company to Host Conference Call/Webcast at 11 a.m. EST Today - LA JOLLA, Calif., Feb. 14 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX ) today announced a str...

Clinical Trial Best Practices: Savvy Marketers Plan Ahead with Early Communication Strategies

CHAPEL HILL, N.C., Jan. 23 /PRNewswire/ -- Marketers, who have the primary responsibility for communicating the results of clinical trials, see coordination and timing activities as top challenges for pharmaceutical companies when communicating trial data. One interviewed marketing executive s...

Deloitte and Nonprofit Roundtable Host Real-World Disaster Exercise as Next Step in Developing Preparedness Plan for Greater Washington Region

Former HHS Secretary Tommy G. Thompson Addresses Executives Before Day-Long Exercise WASHINGTON, Oct. 17 /PRNewswire/ -- Representatives from more than 50 Greater Washington nonprofit organizations meet today with disaster preparedness specialists from Deloitte & T...

Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac

Company Announces Clinical Trial Plans for 4Q07/1Q08 DALLAS, Aug. 20 /PRNewswire-FirstCall/ -- Access Pharmaceuticals, Inc. (OTC Bulletin Board: ACCP) provided today an update on the clinical development plan of ProLindac, its novel DACH platinum polymer prodrug, and announced plans ...

RediClinic Offers Affordable New Plan Clinically Shown to Double a Person's Chance to Stop Smoking

Retail Clinics Provide 12-week Plan to Help People Kick the Habit HOUSTON, Aug. 2 /PRNewswire/ -- RediClinic LLC announced today that it is offering an affordable new program to help people quit smoking. The four-step "Stop Smoking for Good(TM)" plan, available at RediClinics nationwide, in...

BioCryst Updates Peramivir Clinical Development Plan

BIRMINGHAM, Ala., Jan. 23 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX ) today provided an update on activities conducted following release of the preliminary Phase II data and outlined the resulting clinical development plan for intramuscular (i.m.) peramivir. (Lo...

Alliance Pharmaceutical Corp. Updates Oxygent(TM) Clinical Development Plan

SAN DIEGO, Nov. 21 /PRNewswire-FirstCall/ -- Alliance Pharmaceutical Corp. (OTC Bulletin Board: ALLP). Following a Steering Committee meeting last week in China with its partner Beijing Double-Crane Pharmaceutical Co., Ltd. (Double-Crane), Alliance has updated its clinical development plan for...

King Pharmaceuticals Announces Plan to Report Positive Data from Phase III Clinical Trial Evaluating the Combination of Altace with Hydrochlorothiazide

BRISTOL, Tenn.--(BUSINESS WIRE)--Apr 19, 2007 - King Pharmaceuticals, Inc. (NYSE:KG) announced today that the Company has positive top-line results from the Phase III clinical trial evaluating the efficacy and safety of the Company's ALTACE(R) (ramipril) diuretic fixed-dose combination product. The...

King Pharmaceuticals Announces Plan to Present Results from Phase III Clinical Trial Evaluating ALTACE as Monotherapy and in Combination with Hydrochlorothiazide at the American Society of Hypertension Annual Meeting

BRISTOL, Tenn.--(BUSINESS WIRE)--May 8, 2007 - King Pharmaceuticals, Inc. (NYSE:KG) announced today that the results from a Phase III clinical trial for its ALTACE(R) (ramipril) diuretic combination product will be presented at the American Society of Hypertension's Twenty-Second Annual Scientific ...

Palatin Technologies and King Pharmaceuticals Announce Plan To Present Results of Bremelanotide Phase 2b Studies in Men With Erectile Dysfunction

CRANBURY, N.J. and BRISTOL, Tenn., May 09, 2007 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. and King Pharmaceuticals, Inc. today announced plans to present the results from two bremelanotide Phase 2b studies of men with erectile dysfunction (ED). The presenters are Jed Kaminetsky, MD, Cli...

SIRO Clinpharm Completes Successful Implementation of Oracle Life Sciences Application Suite

...linical Trial Management System and Oracle Adverse Events Reporting System. "We are excited to have the rollout of the entire OLSAS as per our plan for the India operations," said Dr. Ajit Nair, President, India Operations, SIRO Clinpharm. "This will help us manage critical tasks in clinical opera...

CTMM Becomes One of the World's Largest Public-Private Partnerships in Translational Medical Research

... said Peter Luijten, CTMM Chief Scientific Officer. With this final project approval, CTMM has fulfilled the initial objectives of its business plan by establishing public-private research consortia to address the world's most prevalent diseases. The CTMM project portfolio now comprises 18 projects...

Montefiore Medical Center and Albert Einstein College of Medicine Herald New Agreement To Continue Forty-Plus Year Historic Relationship

...e medical group practice integrated throughout the Bronx and Westchester; and, a care management organization providing services to 179,000 health plan members. In 2008, The Children's Hospital at Montefiore was ranked as one of "America's Best Children's Hospitals" in US News & World R...

S.C. Medical Home Pilot for Diabetes Enrolls 1,110

...HealthPlan of South Carolina, and the State Health plan and who are patients of Palmetto Primary Care Phys...vely reach out and develop an individual treatment plan for patients. In the first three months, c...eCross, BlueChoice HealthPlan and the State Health plan and their diabetic members in this pilot and belie...

R-Tech Ueno, Ltd. Completes Phase 1 Clinical Study on RK-023

...th full-scale negotiations for partnership at home and abroad." Having obtained the results of the above-mentioned phase 1 clinical study, we plan to promptly conduct a phase 2 clinical study and accelerate our efforts to develop a drug that will become useful for the patients with androgenetic a...

FDA Approves Tekturna HCT(R) as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent

... harm an unborn baby, causing injury and even death. If you get pregnant, stop taking TEKTURNA or TEKTURNA HCT and call your doctor right away. If you plan to become pregnant, talk to your doctor about other medicines to treat your high blood pressure before taking TEKTURNA or TEKTURNA HCT. Do n...

Idenix Pharmaceuticals Successfully Completes Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)

...cessfully completed the proof-of-concept study in HCV-infected patients, we plan to advance IDX184 into a 14-day dose-ranging study in combination with the ...rma AG and GlaxoSmithKline, respectively; changes in the company's business plan or objectives; the ability of the company to attract and retain qualified p...

Exenatide Once Weekly Provided Superior Glucose Control Compared to Lantus(R) in Head-to-Head DURATION-3 Study

... hypoglycemia and patient-reported outcomes. Subjects in both treatment groups are continuing in an open-ended extension study. The companies plan to present the full data set at a major medical meeting and submit the data for publication. About Diabetes Diabetes affects more than...

Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA(TM) in Systemic Lupus Erythematosus

...reatment HGS is working to develop and bring to patients. Assuming positive results in November from our second Phase 3 trial of BENLYSTA, we and GSK plan to submit marketing applications in the United States, Europe and other regions in the first half of 2010." Belimumab is an investigational d...

Results From Drug Trials and New Risk Factors Announced at International Alzheimer's Conference

...ion diet -- or DASH diet -- was associated with higher scores for cognitive functioning. The researchers found that four food categories from the diet plan -- whole grains, vegetables, low-fat dairy foods, and nuts and beans -- may offer benefits for cognition in late life. We need more research before we...

Elbit Imaging Ltd. Announces - Swiss Team Uses InSightec's ExAblate(R) 4000 Brain System to Treat Patients With Functional Brain Disorders

... ExAblate(R) ExAblate is the first system to use the MR guided focused ultrasound technology that combines MRI - to visualize the body anatomy, plan the treatment and monitor treatment outcome in real time - and high intensity focused ultrasound to target brain tissue non-invasively. MR thermometry...

Rigel's R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial

...s clinical trial and the soon to be completed TASKi3 clinical trial, a total of over 670 patients, will guide the design of the Phase 3 trials that we plan to launch with a corporate partner in the first half of next year, " he added. Efficacy Results Treatment N of Pts ACR 20 ACR...

Relievant Medsystems Announces Completion of $20 Million Financing

... pain," commented Paul Goeld, President and Chief Executive Officer of Relievant. "The results from our small pilot study are very encouraging and we plan to initiate a larger study later this year. The multi-center trial is intended to demonstrate the safety and effectiveness of our technology." C...

Acura and King Receive FDA Complete Response Letter Regarding Acurox(R)

...'s Complete Response Letter, and at this stage believe they can respond to the issues raised without conducting any additional studies. The Companies plan to meet with the FDA following submission of their response. About Acurox Tablets Acurox is a patented, orally administered, immediate rele...

Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R)

... BIAL, announced in February this year, Eisai Europe Ltd received a sole license to market, promote and distribute ESL within Europe**. Eisai and BIAL plan to launch Zebinix(R) across Europe during 2009 and into 2010, providing a novel and effective treatment to patients with partial-onset seizures who ar...

Commonwealth Fund Case Study Points to 'Continuous Innovation' at Group Health Cooperative

...ge. Along with its subsidiary carriers, Group Health Options, Inc. and KPS Health Plans, Group Health works to improve the health of more than 607,000 plan members in Washington and Idaho. More than 9,000 staff employed by Group Health and Group Health Permanente, its contracted, multispecialty grou...

Spherix Announces Positive Phase 2 Study Results

...nd without type 2 diabetes. Diabetes Obesity Metab 1999 I 5 285-291) A dose and time-of-administration study was conducted to verify the dosing plan to be used in the phase 3 trial. It was a randomized, open-label, 3 x 3 factorial design for an instant mashed potato load, and a 2 x 3 factorial desi...

Cytel Signs Cooperative Research And Development Agreement With FDA Center for Devices and Radiological Health (CDRH)

...our efforts to help the clinical development community to reduce time-to-market, cut costs, and improve portfolio returns." The CRADA Research plan Abstract The Center for Devices and Radiological Health (CDRH) at the FDA encourages sponsors to use innovative Bayesian designs for clinical trial...

Responses After Completion of Therapy Increase Pixantrone Complete Remission (CR)/Unconfirmed Complete Remission (CRu) Rate to 24% and Overall Response Rate (ORR) to 40% Compared to 7% and 14% for Comparator Agents in Phase III EXTEND Trial in 3rd Line Th

...ll be provided to the U.S. Food and Drug Administration during the 120-day update," stated James A. Bianco, M.D., Chief Executive Officer of CTI. "We plan to request priority review of the NDA from the FDA as we believe that pixantrone would provide patients and physicians with a compelling new option in...

Urologist and Allergist Explore Link Between Allergies and Interstitial Cystitis

...he body are key players in allergic reactions, but their role in the bladder tissue of IC patients has not been clear. Dr. Smith and Dr. Hubbard plan to conduct more research and hope to spark the interest of additional IC and allergy researchers. Meanwhile, these doctors are continuing to help IC p...

VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease

... Guidance from the FDA will be incorporated into the VIA-2291 registration and Phase 3 program, and the company intends to submit its proposed Phase 3 plan to FDA including a request for a Special Protocol Assessment. The Company is currently exploring strategic opportunities for launching this final phas...

Trius Announces Positive Results From Phase 2 Clinical Trial of Torezolid in Patients With Complicated Skin and Skin Structure Infections

...said Jeffrey Stein, Ph.D., Chief Executive Officer of Trius. "Later this year we will complete Phase 1 testing of the IV dosage form of torezolid and plan to merge the oral and IV programs in Phase 3 testing early next year. Our aim is to make torezolid available to physicians and patients as soon as pos...

Takeda to Revise Timing of Alogliptin and Alogliptin/ACTOS MAA Filings in Europe

...ons will be made with a more robust data set necessary to ensure its approval, and as a result, the target timing of MAAs is revised from the original plan of mid-2009 to 2012. Alogliptin, which was discovered by Takeda's wholly owned U.S. subsidiary, Takeda San Diego, Inc. is a dipeptidyl peptidase ...

Ethicon Endo-Surgery Studies Presented at DDW Demonstrate Potential of Pure NOTES Surgery With Company's Toolbox

...d for standard endoscopic or laparoscopic use," said Kenneth Sumner, Ph.D., Vice President, Clinical and Regulatory Affairs, Ethicon Endo-Surgery. "We plan to continue our research to investigate the existing contents of the Ethicon Endo-Surgery Toolbox for natural orifice surgery, as well as develop addi...

Celladon Provides MYDICAR(R) Program Update of First-In-Human Trial for Advanced Heart Failure at American Society of Gene Therapy Annual Meeting

...patients with advanced heart failure at 17 U.S. medical centers. Zsebo adds, "We anticipate completion of Phase 2 enrollment late this summer and plan to report results in the first half of 2010. In addition, we have adequate MYDICAR product manufactured to complete Phase 3 and recently acquired exc...

PharmAthene Submits SparVax(TM) Regulatory Strategy to FDA

...David P. Wright, President and Chief Executive Officer of PharmAthene, noted, "We are pleased to have met our stated goal of submitting our regulatory plan to FDA by May 21st, well ahead of the June 15th submission deadline. We feel we have presented a comprehensive and credible path for the ultimate lic...